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Journal of Cystic Fibrosis 3 (2004) 1PrefaceThe aim of the European Union (EU)-funded Thematic lines for molecular testing and reporting have been or areNetwork on Cystic Fibrosis (2000–2004) was to attempt to
create a unique European platform for scientists involved in
fundamental cystic fibrosis (CF) research for more than 200
European genetic diagnostic laboratories, for CF associa-
tions of families, patients, and clinicians; ethical, legal, and
IPR experts; and representatives of the industry. The net-
work involved all those who wanted to join whether in EU
or non-EU countries, while closely interacting with the
European Cystic Fibrosis Society.
The philosophy of the network grew out of the experience
gained during the previous European Concerted Actions on
Cystic Fibrosis, which, while very successful—four large
quality assessments, regular newsletter, successful regional
training sessions, draft of guidelines for diagnostic labora-
tories and of leaflets for the families, different publications in
peer-reviewed journals, and several symposia in Europe—
showed the necessity of closer interactions with patient
organizations and the clinical profession, as well as with
those involved in the more fundamental research on the
pathogenesis of the disease and the development of new
diagnostics and therapeutics, and with representatives of
industries involved in diagnostics and therapeutics.
This network allowed us to bring together all parties
involved in the same quest—the fight against CF—to make
information available to everybody concerned, to promote
interactions between the parties, and to draft consensus
guidelines on the application of this new knowledge.
A series of more fundamental EU-funded RTD projects
on CF also joined the network over the years. The CFTR
Expression Working Group has done a remarkable job, as
will be clear from the present publication. The very suc-
cessful external quality assessment schemes have already
dramatically improved the quality of genetic testing. Guide-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.045being published, while an internationally approved informed
consent form was developed. Very active exchanges with
the molecular diagnostic industry, and communications
between researchers and clinicians have been established.
The present publication illustrates one of the activities of
the network. A large group of network participants was able,
on a voluntary basis, to collect during 4 years a unique set of
information on techniques, methods, products, and animal
models, and to make this available freely to anybody
interested. The wealth of information and its quality, which
was the result of discussions and thorough review by
participants and expert section editors, makes this a unique
instrument for the CF research community all over the
world. We do not doubt that this will also be a stimulus
for researchers to continue to interact with each other and to
supply this database with additional and newer methods
when they become available.
We salute the drive and expertise of Margarida Amaral
and her team of section editors without whom this source of
unique information would not have seen the light.
Whether the existing CF network will be able to extend
its activities one way or another under the sixth framework
program of the EU remains unclear up to now. What is clear
is that the return of investment by the European community
is undisputable.
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